Intrapersonal and populational heterogeneity of the chemokine RANTES

Clinical Chemistry

Volumn 56, Issue 9, 2010, Pages 1432-1441

  Oran, Paul E ^a   Sherma, Nisha D ^a   Borges, Chad R ^a   Jarvis, Jason W ^a   Nelson, Randall W ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; RANTES;

ARTICLE; CANCER PATIENT; CHEMICAL REACTION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; GENETIC HETEROGENEITY; GLYCATION; GLYCOSYLATION; HEART INFARCTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MASS SPECTROMETRIC IMMUNOASSAY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; TRUNCATION;

CHEMOKINE CCL5; FEMALE; GLYCOSYLATION; HUMANS; IMMUNOASSAY; MALE; MASS SPECTROMETRY;

EID: 77956354082     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.147884     Document Type: Article

References (24)

1. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001; 14:377-86.
2. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217-42.
3. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76.
4. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000;11:152-76.
5. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-9. (Pubitemid 32183031)
6. Lim JK, Lu W, Hartley O, DeVico AL. N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant. J Leukoc Biol 2006;80:1395-404. (Pubitemid 44904978)
7. Oravecz T, Pall M, Roderiguez G, Gorrell MD, Ditto M, Nguyen NY, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997; 186:1865-72. (Pubitemid 27524596)
8. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992; 176:587-92.
9. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, Krensky AM. A human T cell-specific molecule is a member of a new gene family. J Immunol 1988;141:1018-25.
10. Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 2007;3:164-70.
11. Azenshtein E, Luboshits G, Shina S, Neumark E, Shahbazian D, Weil M, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002;62:1093-102. (Pubitemid 34160293)
12. Ng PC, Li K, Leung TF, Wong RP, Li G, Chui KM, et al. Early prediction of sepsis-induced disseminated intravascular coagulation with interleukin-10, interleukin-6, and RANTES in preterm infants. Clin Chem 2006;52:1181-9. (Pubitemid 43794433)
13. Herder C, Haastert B, Muller-Scholze S, Koenig W, Thorand B, Holle R, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005;54 Suppl 2:S11-7.
14. Kaburagi Y, Shimada Y, Nagaoka T, Hasegawa M, Takehara K, Sato S. Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-1alpha, MIP-1beta, and eotaxin) in patients with atopic dermatitis. Arch Dermatol Res 2001;293:350-5. (Pubitemid 32757477)
15. Christodoulakos GE, Lambrinoudaki IV, Economou EV, Papadias C, Vitoratos N, Panoulis CP, et al. Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. Atherosclerosis 2007;193: 142-50. (Pubitemid 46776695)
16. McIntosh M. The need to characterize and report the normal heterogeneity of proteins in clinical biological samples. J Proteome Res 2007;6:2913. (Pubitemid 47310175)
17. Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res 2003;44: 630-9. (Pubitemid 37279713)
18. Proost P, Struyf S, Couvreur M, Lenaerts JP, Conings R, Menten P, et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol 1998;160:4034-41.
19. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV: conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998;273:7222-7.
20. D'Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, et al. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005;68:998-1007.
21. D'Amour P. Circulating PTH molecular forms: what we know and what we don't. Kidney Int Suppl 2006:S29-33. (Pubitemid 43992873)
22. Lopez MF, Rezai T, Sarracino DA, Prakash A, Krastins B, Athanas M, et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010;56:281-90.
23. Borges CR, Rehder DS, Jarvis JW, Schaab MR, Oran PE, Nelson RW. Full-length characterization of proteins in human populations. Clin Chem 2010;56:202-11.
24. Nedelkov D, Phillips DA, Tubbs KA, Nelson RW. Investigation of human protein variants and their frequency in the general population. Mol Cell Proteomics 2007;6:1183-7. (Pubitemid 47099228)